FDAsafety guidance66% confidence
IND Application Reporting: IND Safety Reports
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Eli Lilly; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
This webpage provides an overview of investigational new drug application (IND) safety reporting requirements for sponsors set forth in 21 CFR 312.32 and additional resources, including FDA guidances, related to these requirements.
Supporting Context
- Therapeutic area
- Neurology · CGRP Inhibitor
- Sub-indication
- General
Related signal: FDA Accepts Supplemental Application for Emgality (Galcanezumab)